

# Cristina Chimenti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/456667/publications.pdf>

Version: 2024-02-01

28  
papers

1,819  
citations

567281

15  
h-index

526287

27  
g-index

28  
all docs

28  
docs citations

28  
times ranked

2043  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient. <i>Heart Failure Reviews</i> , 2023, 28, 709-721.	3.9	14
2	Prevalence and Clinical Implications of COVID-19 Myocarditis. <i>Cardiac Electrophysiology Clinics</i> , 2022, 14, 53-62.	1.7	16
3	A proposed strategy for anticoagulation therapy in noncompaction cardiomyopathy. <i>ESC Heart Failure</i> , 2022, 9, 241-250.	3.1	16
4	Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial. <i>European Heart Journal</i> , 2022, 43, 3463-3473.	2.2	28
5	Evidence of systemic endothelial injury and microthrombosis in hospitalized COVID-19 patients at different stages of the disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 571-576.	2.1	23
6	Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 419-429.	2.1	33
7	Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7650.	4.1	17
8	Potential Role of eNOS Genetic Variants in Ischemic Heart Disease Susceptibility and Clinical Presentation. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 116.	1.6	18
9	Myocarditis-associated necrotizing coronary vasculitis: incidence, cause, and outcome. <i>European Heart Journal</i> , 2021, 42, 1609-1617.	2.2	8
10	Role of eNOS genetic variants on ischaemic heart disease susceptibility and acute coronary syndrome presentation. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
11	Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8118.	4.1	148
12	Kappa-light Chain Amyloid Overlapping Hypertrophic Cardiomyopathy With Myocardial Noncompaction. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e010379.	2.6	2
13	The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 86.	2.7	9
14	Primary aldosteronism-associated cardiomyopathy: Clinical-pathologic impact of aldosterone normalization. <i>International Journal of Cardiology</i> , 2019, 292, 141-147.	1.7	14
15	Hypersensitivity Myocarditis and Necrotizing Coronary Vasculitis by Clomipramine Causing Steroid-Sensitive Cardiogenic Shock. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e008736.	2.6	5
16	Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3726.	4.1	63
17	Myocardial expression of Toll-like receptor 4 predicts the response to immunosuppressive therapy in patients with virus-negative chronic inflammatory cardiomyopathy. <i>European Journal of Heart Failure</i> , 2017, 19, 915-925.	7.1	30
18	Early myocardial gadolinium enhancement in patients with myocarditis: Validation of Lake Louise consensus criteria using a single bolus of 0.1 mmol/Kg of a high relaxivity gadolinium-based contrast agent. <i>European Journal of Radiology</i> , 2017, 95, 89-95.	2.6	4

#	ARTICLE	IF	CITATIONS
19	Cushing Syndrome Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, e004569.	2.6	17
20	Microvascular Angina as Prehypertrophic Presentation of Fabry Disease Cardiomyopathy. <i>Circulation</i> , 2014, 130, 1530-1531.	1.6	15
21	Response to Letter Regarding Article, "Contribution and Risk of Left Ventricular Endomyocardial Biopsy in Patients With Cardiomyopathies: A Retrospective Study Over a 28-Year Period" <i>Circulation</i> , 2014, 130, e31.	1.6	1
22	CMR Sensitivity Varies With Clinical Presentation and Extent of Cell Necrosis in Biopsy-Proven Acute Myocarditis. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 254-263.	5.3	177
23	Contribution and Risks of Left Ventricular Endomyocardial Biopsy in Patients With Cardiomyopathies. <i>Circulation</i> , 2013, 128, 1531-1541.	1.6	168
24	Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. <i>European Heart Journal</i> , 2009, 30, 1995-2002.	2.2	461
25	Fatal myocardial co-infection by <i>Toxoplasma gondii</i> and Parvovirus B19 in an HIV patient. <i>Aids</i> , 2007, 21, 1386-1388.	2.2	6
26	Clozapine-Induced Hypersensitivity Myocarditis. <i>Chest</i> , 2004, 126, 1703-1705.	0.8	53
27	Immunosuppressive Therapy for Active Lymphocytic Myocarditis. <i>Circulation</i> , 2003, 107, 857-863.	1.6	434
28	Necrotizing Myocardial Vasculitis in Churg-Strauss Syndrome. <i>Chest</i> , 1998, 114, 1484-1489.	0.8	39